Federated Hermes Inc. Sells 4,805 Shares of CareDx, Inc (NASDAQ:CDNA)

Federated Hermes Inc. decreased its holdings in shares of CareDx, Inc (NASDAQ:CDNA) by 14.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 28,322 shares of the company’s stock after selling 4,805 shares during the period. Federated Hermes Inc. owned approximately 0.05% of CareDx worth $340,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in CDNA. WINTON GROUP Ltd bought a new position in CareDx during the third quarter worth about $72,000. Nisa Investment Advisors LLC grew its position in shares of CareDx by 442.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,440 shares of the company’s stock valued at $77,000 after purchasing an additional 5,253 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in CareDx by 23.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,751 shares of the company’s stock worth $82,000 after purchasing an additional 2,211 shares in the last quarter. Sherbrooke Park Advisers LLC acquired a new stake in CareDx during the 3rd quarter worth approximately $85,000. Finally, Principal Financial Group Inc. lifted its stake in CareDx by 14.3% in the third quarter. Principal Financial Group Inc. now owns 17,635 shares of the company’s stock valued at $123,000 after buying an additional 2,205 shares in the last quarter.

CareDx Trading Up 4.9 %

Shares of CDNA stock opened at $9.72 on Friday. The firm’s fifty day moving average price is $9.67 and its two-hundred day moving average price is $9.34. CareDx, Inc has a 1 year low of $4.80 and a 1 year high of $12.93. The firm has a market capitalization of $503.30 million, a P/E ratio of -2.75 and a beta of 1.51.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($2.21) EPS for the quarter, missing the consensus estimate of ($0.24) by ($1.97). The company had revenue of $65.57 million for the quarter, compared to analyst estimates of $63.66 million. CareDx had a negative net margin of 67.88% and a negative return on equity of 51.40%. The business’s revenue for the quarter was down 20.4% on a year-over-year basis. During the same period last year, the company posted ($0.34) earnings per share. As a group, equities research analysts forecast that CareDx, Inc will post -1.59 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Craig Hallum upgraded shares of CareDx from a “hold” rating to a “buy” rating and raised their price objective for the stock from $12.00 to $15.00 in a report on Wednesday. Stephens reaffirmed an “overweight” rating and set a $15.00 price objective on shares of CareDx in a research report on Wednesday, April 17th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, CareDx has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.